Cable Hill Partners’s Puma Biotechnology PBYI Stock Holding History

Cable Hill Partners’s Portfolio PBYI Stock Details PBYI Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2018 Q3	–	Sell	-22	Closed	-$1K	–	840
2018 Q2	$1K	Hold	22	–	–	﹤0.01%	868
2018 Q1	$1K	Buy	+22	New	+$1.65K	﹤0.01%	864
2015 Q2	–	Sell	-48	Closed	-$11K	–	747
2015 Q1	$11K	Sell	48 -1	-2%	-$214	0.01%	420
2014 Q4	$9K	Buy	+49	New	+$10.9K	0.01%	450

Other funds holding PBYI

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

OrbiMed New York $5.4B AUM 163.13% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

CCM

Consonance Capital Management New York $7.28M AUM 43.59% 1-Year Est. Return

Janus Henderson Group London $209B AUM 37.72% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

PHS

PFM Health Sciences San Francisco, California $1.17B AUM 92.19% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

ACA

Avoro Capital Advisors New York $11.1B AUM 207.82% 1-Year Est. Return

Citadel Advisors Miami, Florida $875B AUM 40.89% 1-Year Est. Return

Cable Hill Partners's PBYI Position: Q3 2018 in Review

Cable Hill Partners sold out of Puma Biotechnology (PBYI) in Q3 2018, closing a stake of 22 shares — an estimated $1K sold.

Cable Hill Partners first reported a position in PBYI in Q4 2014 and held it in 4 quarters. The position peaked at $11K in Q1 2015. 156 funds tracked by Wall St. Rank hold PBYI as of Q3 2018.

Cable Hill Partners reported no remaining Puma Biotechnology position as of Q3 2018 after selling out during the quarter.
Cable Hill Partners sold 22 Puma Biotechnology shares in Q3 2018, an estimated $1K.
Cable Hill Partners first reported a position in Puma Biotechnology in Q4 2014 and held it in 4 quarters.
Cable Hill Partners's Puma Biotechnology position peaked at $11K in Q1 2015.
156 funds tracked by Wall St. Rank held Puma Biotechnology as of Q3 2018.

Based on Cable Hill Partners's 13F filing for Q3 2018, filed 14 Nov 2018.